Caribou Biosciences, Inc.

CRBUSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1619856

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$10.0M	$34.5M	$13.9M	$9.6M	$5.8M
Research and Development Expense	$130.2M	$112.1M	$82.2M	$52.3M	$23.6M
Operating Expenses	$176.6M	$150.5M	$120.3M	$76.6M	$40.1M
Operating Income (Loss)	-$166.6M	-$116.1M	-$106.4M	-$67.0M	-$34.3M
Interest Expense	—	—	—	—	$4.0K
Nonoperating Income (Expense)	$17.5M	$14.2M	$7.0M	$377.0K	$3.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$149.1M	-$101.9M	-$99.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$313.3M	$432.2M	$373.8M	$442.4M	$36.0M
Assets, Current	$219.4M	$338.8M	$260.2M	$391.2M	$24.3M
Cash and Cash Equivalents, at Carrying Value	$16.3M	$51.2M	$58.3M	$240.4M	$41.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$265.0K	$148.0K	$202.0K	$1.2M	$150.0K
Liabilities	$60.4M	$63.8M	$72.9M	$54.5M	$18.2M
Liabilities, Current	$30.7M	$28.3M	$28.1M	$25.8M	$12.4M
Accounts Payable, Current	$2.5M	$3.1M	$1.1M	$4.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$138.2M	-$93.3M	-$91.0M	-$32.5M	-$32.0M
Net Cash Provided by (Used in) Investing Activities	$86.6M	-$68.2M	-$93.2M	-$176.4M	$27.2M
Net Cash Provided by (Used in) Financing Activities	$16.7M	$154.3M	$2.1M	$433.4M	$172.0K
Payments to Acquire Property, Plant, and Equipment	$4.9M	$11.6M	$6.5M	$2.1M	$884.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)